Joel Piser
A5002962795- Bladder and Urothelial Cancer Treatments
- Colorectal Cancer Screening and Detection
- Esophageal Cancer Research and Treatment
- Urinary and Genital Oncology Studies
- Health Systems, Economic Evaluations, Quality of Life
- Epigenetics and DNA Methylation
- Pediatric Urology and Nephrology Studies
- Ureteral procedures and complications
- Genetic factors in colorectal cancer
Golden Gate University
2023
Indiana University School of Medicine
1987
Indiana University – Purdue University Indianapolis
1987
Cecoileal reservoirs were created in 29 patients. Tunneled ureteral implantations along the tenia of cecum provided antireflux mechanism. Plication or tapering terminal ileal segment with ileocecal valve continence The tubular configuration was disrupted either an sigmoid patch, it re-configured a Heineke-Mikulicz type closure to avoid bolus (unit) contractions. Short-term followup examination excretory urography showed no upper tract obstruction. X-rays pouch reflux and interviews revealed...
Urinary comprehensive genomic profiling (uCGP) uses next-generation sequencing to identify mutations associated with urothelial carcinoma and has the potential improve patient outcomes by noninvasively diagnosing disease, predicting grade stage, estimating recurrence risk.This is a multicenter case-control study using banked urine specimens collected from patients undergoing initial diagnosis/hematuria workup or surveillance. A total of 581 samples were analyzed uCGP: 333 for disease...
<p>Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.</p>
<p>Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.</p>
<p>Supplementary Figure 1. Genomic profiles of the validation cohort.</p>
<div>Abstract<p>Purpose: Urinary comprehensive genomic profiling (uCGP) uses next-generation sequencing to identify mutations associated with urothelial carcinoma (UC) and has the potential improve patient outcomes by noninvasively diagnosing disease, predicting grade stage, estimating recurrence risk. Experimental Design: This is a multicenter case-control study utilizing banked urine specimens collected from patients undergoing initial diagnosis/hematuria workup or UC...
<p>Supplementary Figure 1. Genomic profiles of the validation cohort.</p>
<div>AbstractPurpose:<p>Urinary comprehensive genomic profiling (uCGP) uses next-generation sequencing to identify mutations associated with urothelial carcinoma and has the potential improve patient outcomes by noninvasively diagnosing disease, predicting grade stage, estimating recurrence risk.</p>Experimental Design:<p>This is a multicenter case–control study using banked urine specimens collected from patients undergoing initial diagnosis/hematuria workup or...
<p>Supplementary Figure 1. Genomic profiles of the validation cohort.</p>
<p>Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.</p>
<p>Supplementary Figure 1. Genomic profiles of the validation cohort.</p>
<p>Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.</p>
<div>Abstract<p>Purpose: Urinary comprehensive genomic profiling (uCGP) uses next-generation sequencing to identify mutations associated with urothelial carcinoma (UC) and has the potential improve patient outcomes by noninvasively diagnosing disease, predicting grade stage, estimating recurrence risk. Experimental Design: This is a multicenter case-control study utilizing banked urine specimens collected from patients undergoing initial diagnosis/hematuria workup or UC...
<div>AbstractPurpose:<p>Urinary comprehensive genomic profiling (uCGP) uses next-generation sequencing to identify mutations associated with urothelial carcinoma and has the potential improve patient outcomes by noninvasively diagnosing disease, predicting grade stage, estimating recurrence risk.</p>Experimental Design:<p>This is a multicenter case–control study using banked urine specimens collected from patients undergoing initial diagnosis/hematuria workup or...
<p>Supplementary Figure 1. Genomic profiles of the validation cohort.</p>
<p>Supplementary Figure 1. Genomic profiles of the validation cohort.</p>
<p>Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.</p>
<p>Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.</p>